Package Leaflet: Information for the Patient
Adtralza150mg solution for injection in pre-filled syringe
tralokinumab
This medicinal product is subject to additional monitoring, which will allow for the quick identification of new safety information. You can help by reporting any side effects you may get. The last section of the leaflet includes information on how to report side effects.
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
Adtralza contains the active substance tralokinumab.
Tralokinumab is a monoclonal antibody (a type of protein) that blocks the action of a protein called IL-13. IL-13 plays a key role in the occurrence of symptoms of atopic dermatitis.
Adtralza is used to treat adult and adolescent patients from 12 years of age with moderate to severe atopic dermatitis, also known as atopic eczema. Adtralza can be used alone or in combination with other medicines for atopic eczema that are applied to the skin.
The use of Adtralza to treat atopic dermatitis may improve your eczema and reduce the itching and skin pain associated with it.
Do not use Adtralza
If you think you may be allergic, or are unsure, consult your doctor, pharmacist, or nurse before using Adtralza.
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting treatment with Adtralza.
Allergic reactions
Very rarely, medicines may cause allergic reactions (hypersensitivity) and severe allergic reactions called anaphylactic reactions. While using Adtralza, you should look out for signs of these reactions (i.e., breathing problems, swelling of the face, mouth, and tongue, fainting, dizziness, feeling of dizziness (due to low blood pressure), hives, itching, and skin rash).
Stop using Adtralza and contact your doctor or seek immediate medical attention if you notice any sign of an allergic reaction. These signs are indicated at the beginning of section 4.
Intestinal parasitic infection
Adtralza may reduce your resistance to infections caused by parasites. Any parasitic infection should be treated before starting treatment with Adtralza. Consult your doctor if you have diarrhea, gas, stomach discomfort, greasy stools, and dehydration, which could be signs of parasitic infection. If you live in a region where these infections are common or if you travel to that region, consult your doctor.
Eye problems
Consult your doctor if you have new or worsening eye problems, including eye pain or changes in vision.
Children and adolescents
The safety and benefits of Adtralza in children under 12 years of age are still unknown, so do not give this medicine to this population.
Other medicines and Adtralza
Tell your doctor or pharmacist
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medicine. The effects of Adtralza on pregnant women are unknown; therefore, it is preferable to avoid its use during pregnancy unless your doctor advises you to use it.
If you proceed, you and your doctor will need to decide whether to breastfeed or use Adtralza. You should not do both at the same time.
Driving and using machines
It is unlikely that Adtralza will affect your ability to drive and use machines.
Adtralza contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per 150 mg dose; this is essentially "sodium-free".
Follow exactly the administration instructions of this medicine given by your doctor, pharmacist, or nurse. In case of doubt, consult your doctor, pharmacist, or nurse again.
Each pre-filled syringe contains 150 mg of tralokinumab.
Amount of Adtralza to be administered and duration of treatment
Recommended dose in adults and adolescents with atopic dermatitis:
Adtralza is administered by an injection under your skin (subcutaneous injection). Your doctor or nurse and you can decide if you can inject Adtralza yourself.
Inject Adtralza only after your doctor or nurse has taught you how to do it correctly. The caregiver can also inject Adtralza after receiving proper training.
Do not shake the syringe.
Read the "Instructions for use" carefully before injecting Adtralza.
If you use more Adtralza than you should
If you use more medicine than you should or if the dose is administered too soon, consult your doctor, pharmacist, or nurse.
If you forget to use Adtralza
If you have forgotten to inject a dose at the right time, inject Adtralza as soon as possible. The next dose should then be injected according to the established schedule.
If you stop treatment with Adtralza
Do not stop treatment with Adtralza without consulting your doctor first.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Adtralza can cause serious side effects, including allergic reactions (hypersensitivity) such as anaphylactic reactions; the signs may include:
Stop using Adtralza and contact your doctor or seek immediate medical attention if you notice any sign of an allergic reaction.
Other side effects
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and on the carton after EXP. The expiry date is the last day of the month shown.
Store in the original package to protect from light.
Store in a refrigerator (between 2°C and 8°C). Do not freeze.
If necessary, Adtralza can be stored at room temperature up to 25°C in the outer carton for a maximum of 14 days. Do not store above 25°C. Discard Adtralza if not used within 14 days of storage at room temperature.
If you need to remove the carton from the refrigerator permanently, write the date you removed it on the carton and use Adtralza within 14 days. Adtralza should not be refrigerated again during this period.
Do not use this medicine if you notice it is cloudy, discolored, or contains particles.
Medicines should not be disposed of via wastewater or household waste. Ask your doctor, pharmacist, or nurse how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of Adtralza
Appearance of Adtralza and Container Contents
Adtralza is a transparent to opalescent, colorless to pale yellow solution, supplied in a glass pre-filled syringe with a needle shield.
Adtralza is available in single-unit containers containing 2 pre-filled syringes or in multiple containers containing 4 (2 units of 2) or 12 (6 units of 2) pre-filled syringes.
Only some pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
LEO Pharma A/S
Industriparken 55
DK-2750 Ballerup
Denmark
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Belgium/Belgique/Belgien LEO Pharma N.V./S.A Tel: +32 3 740 7868 | Lithuania LEO Pharma A/S Tel: +45 44 94 58 88 |
Bulgaria Borola Ltd Tel: +359 2 9156 136 | Luxembourg/Luxemburg LEO Pharma N.V./S.A Tel: +32 3 740 7868 |
Czech Republic LEO Pharma s.r.o. Tel: +420 225 992 272 | Hungary LEO Pharma Tel: +36 1 439 6132 |
Denmark LEO Pharma AB Tel: +45 70 22 49 11 | Malta E.J. Busuttil Ltd Tel: +356 2144 7184 ext. 125 |
Germany LEO Pharma GmbH Tel: +49 6102 2010 | Netherlands LEO Pharma B.V. Tel: +31 205104141 |
Estonia LEO Pharma A/S Tel: +45 44 94 58 88 | Norway LEO Pharma AS Tel: +47 22514900 |
Greece LEO Pharmaceutical Hellas S.A. Tel: +30 210 68 34322 | Austria LEO Pharma GmbH Tel: +43 1 503 6979 |
Spain Laboratorios LEO Pharma, S.A. Tel: +34 93 221 3366 | Poland LEO Pharma Sp. z o.o. Tel: +48 22 244 18 40 |
France Laboratoires LEO Tel: +33 1 3014 4000 | Portugal LEO Farmacêuticos Lda. Tel: +351 21 711 0760 |
Croatia Remedia d.o.o Tel: +385 1 3778 770 Ireland LEO Laboratories Ltd Tel: +353 (0) 1 490 8924 | Romania LEO Pharma Romania Tel: +40 213121963 Slovenia Medical Intertrade d.o.o. Tel: +386 1 2529113 |
Iceland Vistor hf. Tel: +354 535 7000 | Slovak Republic LEO Pharma s.r.o. Tel: +421 2 5939 6236 |
Italy LEO Pharma S.p.A Tel: +39 06 52625500 | Finland LEO Pharma Oy Tel: +358 20 721 8440 |
Cyprus The Star Medicines Importers Co. Ltd. Tel: +357 2537 1056 | Sweden LEO Pharma AB Tel: +46 40 3522 00 |
Latvia LEO Pharma A/S Tel: +45 44 94 58 88 | United Kingdom (Northern Ireland) LEO Laboratories Ltd Tel: +44 (0) 1844 347333 |
Date of Last Revision of this Leaflet: October 2022
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
Instructions for use with information on how to inject Adtralza are available on the other side of this leaflet.
Instructions for Use
Adtralza
tralokinumab
Injectable Solution in Pre-filled Syringe
Read these instructions before starting to use the Adtralza pre-filled syringes and each time you get a new pack, as they may include new information. You can also talk to your healthcare professional about your disease or treatment.
Keep these instructions for use to be able to consult them again if needed.
Each pre-filled syringe contains150mg of tralokinumab.
The Adtralza pre-filled syringes are for single use only.
IMPORTANT INFORMATION
Important information you need to know before injecting Adtralza
Parts of the Adtralza Pre-filled Syringe:
Storage of Adtralza
Step1: Preparation of the Adtralza Injection
1a: Gather all the necessary materials for the injection
For each dose of Adtralza, you will need:
1b: Remove the Adtralza pre-filled syringe from the refrigerator
Do not usethe Adtralza pre-filled syringes that have been stored at room temperature for more than 14 days.
1c: Allow the Adtralza pre-filled syringes to reach room temperature
Leave the Adtralza container on a flat surface and wait 30 minutes before injecting Adtralza, to allow the pre-filled syringes to reach room temperature (between 20°C and 25°C). This will help make the Adtralza injection more comfortable.
1d: Remove the Adtralza pre-filled syringes from the container
Remove the 2 Adtralza pre-filled syringes from the container one at a time, holding them by the middle of the body (not the plunger rod).
1e: Check the2Adtralza pre-filled syringes
If you cannot use the syringes, discard them in a sharps container and use new syringes.
Step2: Choosing and Preparing the Injection Site
2a: Choose the area where the injections will be administered
2b: Wash your hands and prepare the skin
Step3: Injecting Adtralza
3a: Remove the needle cap from Adtralza
Hold the body of the Adtralza pre-filled syringe with one hand, and with the other, pull the needle cap straight off and throw it away in a sharps container.
3b: Insert the needle
With one hand, gently pinch and hold a skin fold at the cleaned injection site. With the other hand, insert the needle completely into the skin at an angle of 45 to 90 degrees.
3c: Inject the medicine
Push the plunger head firmly with your thumb. You will have injected all the medicine when you can no longer push the plunger.
3d: Release and remove the needle
Lift your thumb off the plunger head. The needle will automatically retract into the body of the syringe and remain inside the body of the syringe.
Discard the used Adtralza pre-filled syringe in a sharps container. See step5“Disposal of Adtralza”.
Step4: Injection of the Second Syringe
To receive the full prescribed dose, you must administer a second injection. Take the second Adtralza pre-filled syringe and repeat steps3and5.
Note
Make sure to administer the second injectionin the same area of the body, but at a minimum distance of 3 cm from the first injection.
Step5: Disposal of Adtralza